marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-06-2024
Trevi Therapeutics Balance Sheet 2011-2024 | TRVI
Annual Balance Sheet Trevi Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-32.2 M | -12.6 M | -36.7 M | -31 M | -57 M | -17.2 M | -16.7 M | - | - | - | - | - | - |
Long Term Debt |
31 K | 2 K | 24 K | 14 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
184 K | 25 K | 120 K | 113 K | 99 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 14.3 M | 257 K | 506 K | 325 K | - | - | - | - | - | - |
Total Current Liabilities |
5.82 M | 13.4 M | 12.7 M | 5.56 M | 5.2 M | - | - | - | - | - | - | - | - |
Total Liabilities |
6.86 M | 15.6 M | 21.4 M | 19.8 M | 5.46 M | 3.18 M | 7.45 M | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-239 M | -210 M | -181 M | -147 M | -114 M | -109 M | -84.4 M | - | - | - | - | - | - |
Total Assets |
89.4 M | 123 M | 38.5 M | 47.1 M | 60 M | 20.5 M | 22.2 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
32.4 M | 12.6 M | 36.8 M | 45 M | 57.3 M | 7.2 M | - | - | - | - | - | - | - |
Book Value |
82.5 M | 107 M | 17.1 M | 27.3 M | 54.5 M | 17.3 M | 14.8 M | - | - | - | - | - | - |
Total Shareholders Equity |
82.5 M | 107 M | 17.1 M | 27.3 M | 54.5 M | -109 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Trevi Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
816 K | 884 K | 949 K | 31 K | 62 K | 93 K | 124 K | 2 K | 2 K | 3 K | - | 24 K | 58 K | 91 K | 123 K | 144 K | 144 K | 144 K | 144 K | 257 K | 257 K | 257 K | 257 K | 46 K | 46 K | 46 K | 46 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
9.94 M | 7.64 M | 6.22 M | 6.86 M | 6.29 M | 5.9 M | 14.5 M | 15.6 M | 18.5 M | 20.9 M | 19.9 M | 21.4 M | 20.2 M | 21.4 M | 19.2 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-276 M | -262 M | -250 M | -239 M | -231 M | -224 M | -216 M | -210 M | -205 M | -196 M | -188 M | -181 M | -172 M | -165 M | -155 M | -147 M | -147 M | -147 M | -147 M | -114 M | -114 M | -114 M | -114 M | -109 M | -109 M | -109 M | -109 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
68.9 M | 73.8 M | 78.6 M | 89.4 M | 95.9 M | 101 M | 116 M | 123 M | 128 M | 81.4 M | 30.4 M | 38.5 M | 31.6 M | 39.1 M | 42.9 M | 47.1 M | 47.1 M | 47.1 M | 47.1 M | 60 M | 60 M | 60 M | 60 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
16.1 M | 13 M | 13.8 M | 32.4 M | 26 M | 13.8 M | 11.7 M | 12.6 M | 66.6 M | 24.7 M | 29.1 M | 36.8 M | 29.3 M | 36.4 M | 41.6 M | 45 M | 45 M | 45 M | 45 M | 57.3 M | 57.3 M | 57.3 M | 57.3 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
59 M | 66.2 M | 72.3 M | 82.5 M | 89.6 M | 95.1 M | 102 M | 107 M | 110 M | 60.5 M | 10.5 M | 17.1 M | 11.4 M | 17.7 M | 23.7 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 60 M | 60 M | 60 M | 60 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
59 M | 66.2 M | 72.3 M | 82.5 M | 89.6 M | 95.1 M | 102 M | 107 M | 110 M | 60.5 M | 10.5 M | 17.1 M | 11.4 M | 17.7 M | 23.7 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | -109 M | -109 M | -109 M | -109 M | -84.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency